Thank you for joining us today. Please note that today's remarks include forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, as described in the cautionary note regarding forward-looking statements and risk factors in our SEC filings. I will now introduce Mitch Gendel, who will lead the formal proceedings of the meeting.
Thank you, Berrin, and good morning, Tilray Brands stockholders. Our first order of business is to confirm that the shares represented at this meeting are sufficient to constitute a quorum, and I confirm that the company properly mailed its meeting notice and proxy statement beginning on September 28, 2026, to all Tilray stockholders of record as of September 24, 2026. We have received an affidavit of mailing to that effect from our proxy distribution agent. In addition, we are joined now by Ms. Leah Grant, who has been appointed to act as inspector of election. The inspector of election has advised us that more than 57.9 million shares, or 39.6% of the outstanding shares of common stock entitled to vote, are in fact represented at this meeting. I therefore declare that a quorum exists.
If you have already sent in your proxy card or voted by internet or telephone, then you do not need to do anything further. If you have not yet voted, you may do so now by clicking on the right corner of your screen at the voting prompt. The polls will close in the next two minutes, so if you intend to vote during the meeting, please do so now. As indicated in Tilray's annual meeting notice and proxy statement, we are here today to consider three items of business. The first proposal to be voted upon is the re-election of each of David Clanachan, Renah Persofsky, and Irwin Simon as Class II directors, to each serve until their three-year term expires or until his or her successor is duly elected. Each of their biographies and qualifications are described in the proxy statement.
Based on the recommendation of Tilray's nominating and corporate governance committee, the board unanimously nominated, and the board recommends a vote for the re-election of each of David Clanachan, Renah Persofsky, and Irwin Simon as Class II directors. The second proposal is the ratification of PricewaterhouseCoopers LLP to serve as Tilray's independent registered public accounting firm for the fiscal year ending May 31st, 2027. Information about this proposal was also included in the proxy statement, and the board unanimously recommends a vote for this proposal. The third proposal to be voted upon is the approval of the governance changes to the company's fifth amended and restated certificate of incorporation. This proposal would declassify the board and eliminate the provision of the charter that allows stockholders to remove directors only for cause. The board unanimously recommended a vote for this governance proposal as well.
I want to remind everyone again that the polls will close within the next half minute, so if you wish to vote, please do so now. We have been informed by the inspector of election that the preliminary votes have been counted, and the polls are now closed. On the first proposal regarding the election of the Class II directors, first, David Clanachan received a majority, or more than 67% of the votes cast, and has been duly re-elected to the board as a Class II director for a new term expiring in 2029. Next, Renah Persofsky also received a majority, or more than 56% of the votes cast, and has been duly re-elected to the board as a Class II director for a term expiring in 2029.
Finally, Irwin Simon received a majority, or more than 60% of the votes cast, and has been duly re-elected to the board as well as a Class II director with a term expiring in 2029. On the second proposal to ratify the selection of PwC as our independent registered public accounting firm, this proposal received a vote to approve of approximately 87% of the votes cast. Therefore, this proposal was duly approved. On the third proposal, the governance proposal, this required a two-thirds majority of outstanding shares in support. Approximately 77% of the votes cast were for approval of this proposal. However, the proposal did not receive a two-thirds majority of outstanding shares voting in support, and therefore was not approved.
As secretary of Tilray Brands, I will file the report of the inspector of election within the minutes of the annual meeting of the company stockholders for those three proposals, and those first two that have been approved. That concludes the formal portion of this meeting. We will next play a video showcasing Tilray's fiscal 2026 accomplishments and highlight of our brands. Thank you. Now I'd like to introduce Irwin Simon, Tilray's Chairman and Chief Executive Officer, who will review our fiscal 2026 accomplishments and share an update on fiscal 2027 and the opportunities ahead.
Thank you very much, Mitch, and what a video. You can see from this video what some of our accomplishments are in some interesting, tough, fun industry. Good morning, fellow stockholders, and thank you for joining us today. Throughout my career, I've never focused on building ordinary companies. I've been interested in seeing opportunities before others see them, building businesses with a competitive advantage, creating brands that have the power to lead entire industries. That is exactly what we're trying to do at Tilray Brands. We've built Tilray Brands with a vision, ambition, and a purpose. Today, Tilray represents approximately $1.2 billion in annualized pro forma revenue, reflecting the full-year contribution of acquired businesses, including most recently, BrewDog. Across our entire company, we have a global presence spanning more than 20 countries, leading market positions across multiple industries, and an exceptional portfolio of products and brands.
In fiscal 2026, international revenue increased across all four of our business segments: distribution, cannabis, beverage, and wellness. We are not dependent on a single market, category, or regulatory outcome. We are not a one-trick pony. What excites me most days as Chairman and CEO, as an entrepreneur, our largest known individual shareholder, is what we can now accomplish with everything we built. Our next chapter is about unlocking the full earning power of Tilray. Yes, it is frustrating at times as we see our share price decline, but building stronger brands, expanding margins, generating cash, and delivering lasting value to our shareholders should ultimately change that. As a shareholder myself, and a large one, I have made as much of a personal stake in that ambition as each of you. My interests are directly aligned with yours.
I win only if you win, and my conviction in Tilray is stronger than it ever has been. I want to address something directly. Our share price, as I said before, does not yet reflect the value that we've built, the value that we will build, and the value that we're building, and I'm not satisfied with that. We're acting on it. We're expanding margins, working on generating cash on a consistent basis, deploying capital where we expect it to earn the strongest returns, and executing with discipline, and taking out non-necessary costs, which we continue to look at. With fuel prices, with utility prices, with costs continuously going up, we continuously look at how we deal with that. Our record fiscal 2026 results, our strong balance sheet, and the cost action we've already taken are that foundation.
That means managing working capital tightly, controlling costs, and making sure our growth translates into cash generation. I also want to address, which I'm shown, talked about a lot, dilution. We do not have banks, so we use ATMs. We use at-the-market offerings to finance selective acquisitions that are accretive and investments that are accretive to our business. We are working to need fewer stock offerings by generating cash, reducing debt, and lowering our costs. We believe we assembled the right businesses, the right assets, the right team at the right time. There's no other company quite like Tilray Brands, and that is to our advantage. Fiscal 2026 was a landmark year for Tilray. We reported a record net revenue of $915 million, up 11% year-over-year. Record gross profits, record adjusted EBITDA of $61 million, and also up 11% across all our platforms.
We launched almost 200 new products globally. We've strengthened our balance sheet, ending fiscal 2026 with approximately $235 million in cash and restricted cash and marketable securities, even after spending approximately $100 million on the BrewDog acquisition and investments in the business, and improved operating cash flow by about $25 million year-over-year. We expanded our global footprint, acquired outstanding brands, including BrewDog, at an exceptional price, and advanced our market leadership, and we carry that momentum into our fiscal 2027. In fiscal 2026, we made debt reduction of approximately $40 million, including converting $17 million of convertible notes into equity. That avoided a cash outflow and saves us about $1 million in interest each year. We repaid about $25 million of term debt, saving another $1.7 million a year.
Since fiscal year-end, we've reduced the convertible note balance by another $40 million, which reduces our interest by another $2 million. We did it while acquiring and investing in BrewDog, and what a great acquisition that has been and will be. Today, we're one of the leading cannabis companies in the world, in a tough industry, with one of the strongest EU GMP-certified medical cannabis footprints and operations anywhere. We're the number one craft beer supplier in the U.K. today, with approximately a 50% share of the U.K. craft beer market, and the fourth-largest craft brewer in the United States. We're the global leader in hemp foods and wellness, an established pharmaceutical distribution business in Europe, and an international hospitality operator. Think about the power of that combination, and how we have consolidated that into one company, Tilray Brands.
Our brands, manufacturing capability, distribution networks, and international expertise reinforces one another. Together, they give us scale and reach that extend well beyond any individual business or any other company like this. We can introduce new products, enter new markets, bring additional volume through infrastructure we already own. That is the strength of our business model. Look at what we accomplished in beverage in just a few years. We built a global beverage business with leading brands, established distribution networks, and world-class brewing capabilities across North America, Europe, and Australia. That platform is also opening new markets for our U.S. brands. During fiscal 2026, we launched 23 American craft beers and non-alcoholic beverages from nine Tilray brands into the United Kingdom, and every shipment sold out in less than two weeks. BrewDog is a powerful example of our ability to execute quickly.
We completed BrewDog in four transactions for about $54 million. This is a business once valued at $2 billion. In approximately nine months since the acquisition, we've repositioned the business, reignited excitement around the brand, and returned the brand to profitability under our ownership, where it's not been for a long time. Since the relaunch, Punk IPA sales across BrewDog's top six off-trade retailers have nearly tripled year-over-year, up 187%. We've also secured more than 9,000 new distribution points and launched eight new on-trade partnerships. That is what happens when you combine a great brand with experienced leadership, commercial discipline, and the right operating infrastructure. Not everything happens immediately. Good things take time. We believe that approach can be replicated across our portfolio to strengthen our brands and unlock shareholder value for us all. Our international hospitality business provides another competitive advantage.
Through our bars and taprooms, we connect directly with consumers, introduce new products, build brand loyalty, and gain valuable insight into consumer preferences. The World Cup showed the power of that model. Our pubs welcomed more than 28,000 guests during the tournament. Our summer World Cup campaign and the launch of our new "Under New Ownership" and "Choose Craft" campaign have turned BrewDog around. They have brought guests back into our pubs, put the brand back in front of consumers, and delivered real momentum at retail, while consumers thought BrewDog was dead. We're continuing to grow the BrewDog brand globally through expanded distribution partnerships and new BrewDog bars in key markets. The result is a stronger BrewDog, winning market share, expanding its reach, and becoming a larger part of Tilray's growth story on a global basis.
We know how to identify value in business, mobilize our teams, and deliver results. We are applying that same discipline to our U.S. beverage business, and I will come back to that later. Turning to cannabis, I continue to believe this industry represents one of the most significant developments in global healthcare and consumer products. Yes, it has taken longer than we expected, but it is still to come, and Tilray is exceptionally well-positioned to lead it. We have one of the most sophisticated cannabis operations in the world, combining EU GMP pharmaceutical-grade production, exceptional product quality, competitive production costs, and established international markets. But remember, this is in agriculture. It takes 12 weeks to grow and cultivate, so sometimes things do not happen when they are supposed to. Our operations in Portugal and Germany give us a distinct advantage in international medical cannabis.
We have expanded our Portugal capabilities to close to 35 metric tons. We pair EU GMP-certified production with regulatory expertise and established commercial relationships to reliably serve patients across the international market. We delivered record international cannabis results in 2026. International cannabis revenue grew 34%. We hold 45% of the German medical cannabis oil market. Over the last 12 months, our medical cannabis flower volume has grown four times, and our share of German flower market has risen approximately three and a half times. We built out our European headquarters in London, advanced our supply chain, and we have acquired Lyphe, which extends our reach across the full patient value chain and gives a direct-to-patient insight. We are now strengthening Lyphe's operations, making it more technology-enabled and improving the patient journey. Lyphe gives us a strong platform in one of Europe's largest medical cannabis markets.
As you see, Boots just announced in the U.K. that they will be selling medical cannabis for prescriptions. These capabilities take years to build. We have them today. We are growing our presence across Europe, in Germany, the U.K., Poland, Italy, Spain, and France, and entering new markets beyond it. As more countries open up patient access to medical cannabis, we are focused on gaining market share, introducing differentiated products, and becoming a trusted supplier to healthcare professionals and patients worldwide. Our pharmaceutical distribution business strengthens our position in Europe. Through CC Pharma, we have established infrastructure, deep commercial relationships, and access to one of Europe's most important pharmaceutical markets. Our pharmaceutical distribution business grew revenue 21% year-over-year in fiscal 2026 to $327 million. The combination of medical cannabis, pharmaceutical distribution gives Tilray a distinctive position in European healthcare.
In Canada, we operate one of the industry's largest and most advanced cannabis production platforms. We have a leading brand, number one market share position in pre-rolls, beverages, oils, and chocolate edibles. During fiscal 2026, we delivered strong performance across pre-rolls, edibles, vapes, demonstrating our ability to anticipate consumer preferences and bring relevant products to the market. Our focus is on product innovation, product differentiation, market leadership, and of course, profitability. Importantly, our cannabis strategy is built around commercial viability, business operating in established markets today, with the capabilities to capitalize on regulatory development around the world. In wellness, Manitoba Harvest gives us a leading position in hemp-based nutrition, with trusted brands, established in retail distribution, and innovative products aligned with consumers, increasing interest in health and wellness. In fiscal 2026, our wellness revenue grew 9% to $66 million.
We hold roughly 60% of the Manitoba Harvest hemp food category, and HiBall Energy has more than tripled since we acquired the brand from ABI. Let me turn to fiscal 2027 and what we are doing to build and continue this momentum. in the U.S., we are building a more focused beverage business around our priority brands, core markets, and national commercial capabilities. Since the end of fiscal 2026, we have taken decisive steps and will continue to take these steps to improve the economics of that business. We have optimized our brewing network from 10 facilities to six, and we will look at where we should do more, and are consolidating our national distributor network. These initiatives are targeting approximately $20 million in annualized cost savings by the end of fiscal 2028, while increasing capacity, utilization, and improving our operating efficiency.
On January 1st of this year, of January 1st, I am sorry, of 2027, we will launch our exclusive U.S. partnership with Carlsberg, which, let me tell you, is exciting. Bringing Carlsberg Elephant, 1664 Blanc into our U.S. beverage platform is exciting for Tilray. And so far, our presentations have gone extremely well. We are targeting 1 million cases in the first year, at least, leveraging the brewery's sales team and distribution infrastructure we already have in place. What excites me about this partnership is what they say about Tilray. We have become a company with world-class international beverage brands that can turn to for manufacturing, commercial expertise, and access to one of the world's largest beverage markets. Carlsberg demonstrates that, how we can generate incremental revenue, earnings from the assets we already own, and that is a compelling economic model. We did not pay for Carlsberg.
Carlsberg worked with us as they saw who was their right partner. This accretive agreement leverages our distribution scale and expertise and drives improved utilization across our beverage facilities. With higher yields across our Canadian cannabis cultivation sites, we are also making our Canadian production network work more productive. We are closing our Foss facility and consolidating cultivation into our established Masson facility, and pre-roll production into our Cayuga facility, targeting approximately $10 million in annualized cost savings, with the full run rate beginning in fiscal 2028. At Masson, we are working on re-certifying for international exports. We have the potential to increase annual cultivation capacity from approximately 32.5 metric tons- 50 metric tons, supporting demand across domestic and international markets. Across our businesses, we are focused on maximizing the productivity and financial contribution of the assets we have assembled.
Together, our largest U.S. beverage and Canadian cannabis initiatives are targeting approximately at least $30 million in combined annual savings, with the full run rate expected by fiscal 2028. We are strengthening our balance sheet, enhancing our financial flexibility. We are directing capital towards investments that can deliver the strongest returns. Our financial outlook reflects that focus. We recently raised the lower end of our fiscal 2027 adjusted EBITDA guidance, and now expect to deliver between $70 million and $75 million, representing an increase of approximately 15%-23% over 2026. That is the direction in which we intend to take this company. I am confident in that path. We have built it with optionality so we can act upon opportunities as they emerge. As we have said before, we are ready when the U.S. rescheduling cannabis, and we are ready for the medical cannabis opportunity that hopefully will happen.
We will continue to optimize our business and make it smarter. We are embracing AI and advanced technology across our businesses. I believe AI will fundamentally change how consumer companies operate, innovate, and compete, and we will be right there with it. We see applications across cannabis cultivation, strain development, quality control, beverage innovation, supply chain management, and commercial decision-making. Our objective is to increase productivity, accelerate innovation, and make better business decisions. Technology combined with the expertise of our people, the experience of our people, the hard work of our people, can become a meaningful competitive advantage for Tilray. I have always believed that great companies are built the same way, by seeing opportunities early, making decisive investments, making decisions, developing exceptional people, and executing with discipline. That is how we have built Tilray. Our priorities are clear: profitable growth, strong margins, cash generations, and an attractive return on invested capital.
Every dollar we invest must have a purpose. Every business must contribute to the strength of the enterprise, and every strategic decision must be evaluated through the lens of long-term shareholder value. Everything we do comes back to one thing: building lasting value for the owners of this company. I am proud of what we have accomplished at Tilray since 2019. We have established leadership across multiple industries, assembled exceptional brands, built an international operating infrastructure that distinguishes us from other competitors. We have an experienced leadership team and talented people around the world to share my ambition for this company. We have a clear mandate: translate our competitive advantages into stronger financial performance and meaningful shareholder returns. I am incredibly bullish on Tilray's future. I believe in our strategy, and I believe in our people, I believe in our brands, and I believe in our products.
To our employees around the world, our Board of Directors, our business partners, and most importantly, our shareholders, thank you for your commitment and confidence in Tilray Brands. We set out to build a different kind of global company. Our ambition is to establish Tilray as one of the most successful companies across the industries we serve, recognized for the strength of our brands, the quality of our execution, and the returns we deliver to our shareholders. I believe the greatest value we will create at Tilray is still ahead of us, and I have never been more determined to deliver it. Finally, to our customers across the U.S., as you head into Thanksgiving, get out there, try our brands, share them with friends and family. We have something for everybody, and they make great host gifts. To everybody, happy Thanksgiving, and thank you very, very much for your support.
There are no further business. I do hereby declare the 2026 Annual Shareholder Meeting adjourned. Thank you.
This concludes today's annual meeting. You may now disconnect.